Appropriate Utilization of Drug Tests for Pain Management Patients
Drug testing is becoming routine in the management of patients who are prescribed opioid therapy for chronic pain. If the unique characteristics of this clinical application are not well understood, routine drug testing can be costly. This presentation will focus on an approach to managing drug testing that is designed to maximize medical utility while minimizing inappropriate utilization.
Originally presented on September 25, 2012 in Salt Lake City, Utah.
Gwendolyn A. McMillin, PhD
Medical Director of Toxicology Laboratories, ARUP Laboratories
Co-director, Pharmacogenetics, ARUP Laboratories
Associate Professor, Department of Pathology, University of Utah School of Medicine
Dr. McMillin has been involved in drug testing for more than 20 years. She is currently focused on the development and promotion of strategies, including test optimization, novel analytical techniques, alternate specimens, and algorithms for interpretation of results, which improve utility and quality of laboratory testing. She has published more than 100 manuscripts, review articles, and original research in this area, and actively participates in several professional organizations. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.
- List appropriate reasons to request quantitative(e.g., confirmation) tests.
- Understand utility of blood for drug testing.